Holen Sie sich die Stockscreener-App
19.03
1.60%
0.30
Handel nachbörslich:
19.20
0.17
+0.89%
Schlusskurs vom Vortag:
$18.73
Offen:
$18.19
24-Stunden-Volumen:
4.62M
Relative Volume:
3.63
Marktkapitalisierung:
$1.51B
Einnahmen:
$288.00K
Nettoeinkommen (Verlust:
$-228.06M
KGV:
-3.9076
EPS:
-4.87
Netto-Cashflow:
$-168.82M
1W Leistung:
+6.61%
1M Leistung:
-3.84%
6M Leistung:
+53.72%
1J Leistung:
-6.85%
1-Tages-Spanne:
$18.19
$19.45
1-Wochen-Bereich:
$17.06
$23.65
52-Wochen-Spanne:
$11.40
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie VRDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
19.03 | 1.51B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$18.7 Based On Its Intrinsic Value? - Simply Wall St
Wells Fargo Downgrades Viridian Therapeutics (VRDN) - MSN
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap DownTime to Sell? - MarketBeat
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) - Seeking Alpha
Wells Fargo & Company Reiterates "Equal Weight" Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by State Street Corp - Defense World
State Street Corp Has $54.14 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation - Seeking Alpha
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - MSN
When (VRDN) Moves Investors should Listen - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 5.7%Here's What Happened - MarketBeat
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views - Benzinga
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics sees stock soar after Phase III TED success - Yahoo Finance
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $47.00 at Royal Bank of Canada - MarketBeat
Viridian veers upwards on Phase III success - The Pharma Letter
Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints - Yahoo Finance
Viridian Therapeutics' SWOT analysis: thyroid eye disease stock poised for growth - Investing.com India
Lord Abbett & CO. LLC Takes $8.92 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Wellington Management Group LLP Decreases Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Given Buy Rating at HC Wainwright - Defense World
Viridian taking on Amgen in TED market - BioCentury
Viridian Continues Building Case For Veligrotug In TED - Citeline News & Insights
Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data - MSN
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap UpHere's What Happened - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Receives Buy Rating from HC Wainwright - MarketBeat
Viridian stock soars 25% on Phase 3 data for veligrotug (VRDN:NASDAQ) - Seeking Alpha
Viridian shares soar after latest trial success for thyroid eye disease drug - Reuters.com
Viridian Therapeutics (VRDN) Gains Momentum In Pre-Market Trading - Stocks Telegraph
Viridian Therapeutics Achieves Milestone in Phase 3 Trial - TipRanks
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Business Wire
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Y Intercept Hong Kong Ltd Invests $660,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Exome Asset Management LLC Acquires New Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 - Business Wire
Viridian Therapeutics Enters Oversold Territory (VRDN) - Nasdaq
Point72 Asset Management L.P. Purchases Shares of 34,627 Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Two Sigma Advisers LP Cuts Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Charles Schwab Investment Management Inc. Increases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
(VRDN) Technical Pivots with Risk Controls - Stock Traders Daily
Viridian Therapeutics' SWOT analysis: biotech stock poised for growth in TED market - Investing.com Nigeria
Polar Asset Management Partners Inc. Purchases 53,100 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
425,000 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Parkman Healthcare Partners LLC - MarketBeat
Viridian Therapeutics Awards Major Stock Options Package to Expand Team with 10 Key Hires - StockTitan
33,475 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Purchased by PDT Partners LLC - MarketBeat
Fmr LLC Has $254.42 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Walleye Capital LLC Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Fisher Asset Management LLC Increases Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viridian Therapeutics Inc-Aktie (VRDN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mahoney Stephen F. | President and CEO |
Sep 27 '24 |
Buy |
23.33 |
21,400 |
499,262 |
21,400 |
| Fairmount Funds Management LLC | Director |
Sep 13 '24 |
Buy |
18.75 |
1,600,000 |
30,000,000 |
3,445,813 |
| Fairmount Funds Management LLC | Director |
Jan 22 '24 |
Buy |
21.00 |
476,190 |
9,999,990 |
1,839,954 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):